Medico Remedies Ltd. · NSE:MEDICO
Medico Remedies — Q2 FY2023 Earnings Presentation
18 slides from Medico Remedies's earnings presentation, Nov 15, 2022
Slide 1: Exchange filing cover letter for investor presentation
Date: 15th November, 2022 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers 5th Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex, Bandra (East) Mumbai – 400001 Mumbai-400051 Scrip Code: 540937 Symbol: MEDICO Dear Sir/Madam, Sub: Investor Presentation for Q2 FY 20
Slide 2: Q2FY23 Financial Results
Q2FY23 Financial Results November 12, 2022
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Medico Remedies Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securi
Slide 4: About Medico Remedies Limited
About Medico Remedies Limited Established in 1994, Medico is a formulation manufacturing company with focus on anti-infective, Beta- Lactums, cephalosporin, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins, haematinics and other supplements. Values • Customer satisfaction above
Slide 5: Financial Summary
Financial Summary Financial Summary Q2FY22 Q1FY23 Q2FY23 (INR cr) Sales 29.5 33.1 40.5 EBITDA 2.2 -0.2 3.1 PAT 1.7 0.4 2.9
Slide 6: Profit & Loss statement - Quarterly
Profit & Loss statement - Quarterly Particulars (INR cr) Q2FY23 Q1FY23 Q4FY22 Q3FY22 Q2FY22 Q1FY22 Revenue 40.5 33.1 32.3 30.1 29.5 29.1 Gross Profit 10.6 6.8 9.5 9.4 9.7 5.1 GPM(%) 26.1% 20.5% 29.6% 31.0% 32.9% 17.6% EBITDA 3.1 -0.2 2.6 1.8 2.2 0.6 EBITDAM (%) 7.8% -0.6% 8.2% 5.9% 7.3% 2.1% Depreci
Slide 7: Quarterly Performance
Quarterly Perfromance 34 7.0% 33.14 33 32.28 6.0% 32 5.0% 5.8% 31 4.0% In Q1FY23, Medico’s Sales grew by 14% 30 3.0% YoY and PAT increased by 157% YoY. 29.07 29 2.0% 28 1.1% 1.0% 0.5% 27 0.0% Q1FY22 Q4FY22 Q2FY23 Sales (Inr cr) PATM (%)
Slide 8: 5 year Financial Performance
5 year Financial Performance Revenue & Margins 150 122 121 10.0% 7.2% 8.0% 98 89 100 5.6% 7.6% 6.0% 61 4.8% 5.1% 5.9% 5.6% 4.0% 50 3.2% 3.8% 3.7% 4.0% 2.0% 0 2.0% 1.6% 1.8% 2.1% 0.0% FY18 FY19 FY20 FY21 FY22 Sales EBITDAM (%) EBITM (%) PATM (%) Debt to Equity Return Ratio 15% 60 0.48 0.60 0.47 0.46
Slide 9: Profit & Loss Statement - Annually
Profit & Loss Statement - Annually Particular (INR cr) FY17 FY18 FY19 FY20 FY21 FY22 CAGR FY17-FY22 Revenue 54.4 61.0 97.7 88.6 122.4 121.0 17.3% Other Income 0.4 0.9 1.9 2.1 1.0 2.0 Total Revenue 54.8 61.9 99.6 90.7 123.4 123.0 COGS 38.7 43.5 79.5 67.2 92.2 87.3 Gross Profit 16.0 18.4 20.1 23.5 31.
Slide 10: Balance Sheet
Balance Sheet Particulars (Inr cr) FY17 FY18 FY19 FY20 FY21 FY22 Share Capital 3.2 4.1 4.1 4.1 4.1 16.6 Reserves and Surplus 13.2 22.5 24.1 25.7 28.3 20.7 Total Equity 16.4 26.7 28.2 29.9 32.5 37.3 Long Term Borrowings 10.8 2.2 2.4 4.7 5.0 0.9 Deferred Tax Liabilities (Net) 0.0 0.1 0.2 0.2 0.2 0.0 O
Slide 11: Ratio
Ratio FY18 FY19 FY20 FY21 FY22 Debt to Equity (x) 0.47 0.48 0.46 0.46 0.28 RoE (%) 5% 6% 5% 8% 13% ROCe (%) 9% 8% 8% 10% 15%
Slide 12: Geographical Revenue Breakup
Geographical Revenue Breakup Fy22 YANGON MYMANAR 6% BELIZE 1% APAPA LAGOS, NIGERIA 12% PUERTO CORTES HONDURAS 20% CAUCEDO DOMINICAN REPUBLICAN POTI GEORGIA 26% 2% NORTH MAINLA, PHILIPPINES 8% BHUTAN 2% PANAMA CITY 0% DAKAR SENEGAL, MALI IRAQ 6% 6% MORESBY, PAPUA NEW GUINEA 0% MONROVIA,LIBERIA COLOMB
Slide 13: Manufacturing Facility
Manufacturing Facility Tablets: Product Particulars Units in millions Installed Capacity (No. of Palghar Facility 122.6 Units/ month) Capsules: Product Particulars Units in millions Installed Capacity (No. of Palghar Facility 36 Units/ month) Dry Syrup: Product Particulars MT in millions Installed C
Slide 14: Global Presence
Global Presence Medico Remedies is counted as a trusted manufacturer, supplier and exporter of wide range of pharmaceuticals products in both General and B-Lactam categories. The company is empowered with the latest WHO-GMP and ISO 9001-2008 certifications. The state of the art manufacturing unit ha
Slide 15: Product Portfolio
Product Portfolio FAitecico Remedies Lt
Slide 16: Board of Directors
Board of Directors Mr. Haresh Mehta, Chairman and CFO Currently, Mr. Haresh Mehta aged 62 is the Chairman & Chief Financial Officer of our Company. He is a founding member of our Company. He now looks after the Financial and Legal departments of our Company. He holds Bachelor’s Degree of Pharmacy fr
Slide 17: Key Milestone
Key Milestone 1999-02 – Set up 1994 – Incorporated as 2016 - Renewed WHO- Manufacturing Facility Medico Remedies GMP Certification for for Beta-Lactam and Private Ltd manufacturing facility Formulation 2017 - Renewed ISO- 9001:2015 Certification 2016 - Purchased 2018 - Listed on BSE for manufacturin
Slide 18: Thank You
KA medico Remedies Ltd Thank You